Crossmark

Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata

Crossref DOI link: https://doi.org/10.1016/j.abd.2023.07.003

Published Print: 2024-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Muzy, Guilherme http://orcid.org/0000-0002-7302-4113
Funding

Funding for this research was provided by:

Eli Lilly and Company

Pfizer
License Information

Text and Data Mining valid from 2024-05-01

Text and Data Mining valid from 2024-05-01

Version of Record valid from 2024-01-27
More Information

This article is maintained by: Elsevier

Article Title: Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2023.07.003

Content Type: simple-article

Copyright: © 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.